Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT00613847
Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab
Overview
The purpose of this study is to learn more about how a new study agent works inside the body. This study agent is a protein called 68Ga-F(ab')2-trastuzumab fragments (HERScan). This is a radioactive tracer that was developed at MSKCC to target the HER2 protein on cancer cells. By giving this tracer to patients whose cancers have the HER2 protein, we hope to be able to see the level of HER2 on the cancer cells using PET scanning.
Sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Contacts
Jorge Carrasquillo, MD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT00613847Eligibility
Inclusion
- Measurable or evaluable disease
- Patients must have had routine disease staging studies with CT scan, FDG PET/CT scan, bone scan and/or MRI within 8 weeks of enrollment onto this trial
- Karnofsky Performance Score ≥ or = to 60
- Patients with invasive solid tumors.
- Registered patient at MSKCC
Exclusion
- Pregnancy Test to be performed on female patients of childbearing potential within 24hrs before administration of radioactive material.
- Claustrophobia/pain or any other disability leading to inability to lie still for the duration of the scanning procedure.
- Patients with known sensitivity or contraindication to Herceptin.
Share your feedback
Help us improve your experience